Provider review
SnagRx Review: The 15% Is Right and the 1-2 lbs a Week Is Not
SnagRx makes two weight-loss claims in one sentence and only one survives its own evidence. "Lose up to 15% of your body weight" is close to what STEP-1 reported for semaglutide — the registry records −15.6% over 68 weeks. "(1-2lbs per week)" is not. That 15.6% across 68 weeks averages about 0.23% of starting weight a week, and for one to two pounds a week to match it you would need to start north of 400 lb.
Correction, August 2026
This review previously said: “No compounding category is stated anywhere, and "US-Certified Pharmacy" names no certifying body. […] SnagRx's FAQ carries the question "What States/Jurisdictions are eligible?" and publishes no list, included set or excluded set on the page.”
That was wrong. Both were absence claims, and an absence claim is only as good as the sweep behind it. These were written from the home page and the product listings; the answers were inside the collapsed FAQ accordions and the terms of use, which the original check did not open. We cannot tell you whether the wording changed since 11 August or was there all along, which is precisely why an absence needs a stated method rather than a look.
It now says: SnagRx does state its compounding category. Its FAQ answer to "Where do my prescriptions come from?" reads "dispensed by U.S.-based 503A compounding pharmacies", says they follow USP 795 and USP 797, and adds that compounded medications "are not FDA-approved, but 503A compounding pharmacies are licensed by state pharmacy boards". It also publishes its coverage — "all US States except Louisiana", with services in Nebraska limited to patients 19 or older — and names four partner pharmacies rather than one, each with a street address and a phone number. The "US-Certified Pharmacy" badge still names no certifying body, and the home page still describes the facilities as "FDA-regulated", which the FAQ answer contradicts.
SnagRx is worth reading carefully because it gets the hard part right and the easy part wrong. Its headline percentage is honest — "up to 15%" is what semaglutide's phase 3 trial actually produced, and plenty of companies reviewed here inflate that number freely. Then it puts "(1-2lbs per week)" in the same breath, and that is a different claim entirely: STEP-1's result averaged roughly a quarter of a percent of body weight per week, which for an ordinary starting weight is well under a pound. The rate is two to four times the evidence, the same 15% is applied to two molecules with different trial results, and both trials tested approved drugs rather than the compounded ones being sold. Against that, it names its pharmacy with an address and a phone number, and it prints the not-FDA-approved disclosure that two companies we've reviewed have open letters for omitting. It is also the same company as Embody, which nothing on either site mentions.
Worth trusting if
- You want the pharmacy named, because SnagRx names four — Triad Rx, RedRock, Health Warehouse and Precision Compounding — with addresses and phone numbers.
- You want the compounding category in writing, because its FAQ says 503A and says those pharmacies are licensed by state boards, not by FDA.
- You will commit to twelve months, because that is the only plan that charges the price the home page advertises.
Be skeptical if
- You are buying one month at a time, because the month-to-month rung costs more than the figure on the home page.
- You budget by the calendar month, because the authorization charges every 28 days — 13 charges a year, not 12.
- You want a forecast that came from evidence, because the one in the signup is your own goal-weight gap read back at about 4.8 lb a week.
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens snagrx.com. A link is not a recommendation to take anything.
Provenance
What SnagRx actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded Semaglutide Injections — Read 2026-08-10, the homepage advertised $69 against a struck-through $299, and this note inferred that the undiscounted figure was what a month costs without committing. Re-checked 2026-08-25 by walking the signup to the plan picker: that inference was wrong. The plan screen sets four rungs against the same anchor — $99 a month with no commitment, $89 on a three-month plan, $79 on six months, and the advertised $69 only on the twelve-month plan. So the headline is the annual-prepay rate, and the month-to-month buyer pays more than it. The checkout authorization charges every 28 days rather than monthly, which is 13 charges in a year, or $1,287 at the month-to-month rate. A footer promises you can "lock that pricing in for life" inches from a clock counting down to the price rising.
- Compounded Tirzepatide Injections — Advertised at $119, and the anchor beside it depends on which page you are standing on. Read 2026-08-10 the homepage card struck through $399, and its sibling brand Embody, the same operating company, struck through $349 for the same compound. Re-checked 2026-08-25: the homepage card still carries the higher anchor, and the plan picker inside the signup carries the lower one for the same product on the same day. Two undiscounted prices for one compound, on one company's own pages. We did not walk the tirzepatide plan screen, so we cannot say what a single month of it costs — on the semaglutide side the advertised figure turned out to be the twelve-month rate, so ask before assuming $119 is what one month costs.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to SnagRx.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from SnagRx’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded Semaglutide InjectionsSemaglutide · Compounded (503A)Claim reaches past the trials
“Lose up to 15% of your body weight (1-2lbs per week) with medically supervised safe & effective treatment from the comfort of your home. […] It's not cheating, it's science! […] Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality.”
Read on the SnagRx site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Registry-verified 2026-08-11: primary outcome "Change in Body Weight (%)", timeframe "Baseline (week 0) to week 68", reported as −15.6% on semaglutide 2.4 mg against −2.8% on placebo. The published paper reports −14.9% on a different estimand; both are real and the difference is the analysis, not the trial. It tested Novo Nordisk's approved injectable, not a compounded preparation.
The percentage is defensible and the weekly rate is not, and they are printed in the same sentence. STEP-1's −15.6% was measured over 68 weeks, which averages roughly 0.23% of starting body weight per week. For "1-2 lbs per week" to match that average a patient would have to start at about 435 to 870 lb; at any weight this drug is ordinarily prescribed at, the claim is two to four times the rate the trial produced. In fairness: loss on these drugs is front-loaded, so the first weeks do run faster than the average — the objection is that a peak rate is being presented as the rate, with no period attached. And the trial tested the approved product; what SnagRx dispenses is compounded and has never been through a registered trial. SnagRx does state that compounded medications are "not FDA-approved or evaluated for safety, efficacy, or quality" — but not next to the 15%.1
Compounded Tirzepatide InjectionsTirzepatide · Compounded (503A)Claim reaches past the trials
“Compounded Tirzepatide Injections — In Stock · $399 $119. […] Lose up to 15% of your body weight (1-2lbs per week) with medically supervised safe & effective treatment from the comfort of your home.”
Read on the SnagRx site, August 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Registry-verified 2026-08-11: Completed, phase 3, 2,539 participants over 72 weeks, testing the approved injectable tirzepatide at a titrated therapeutic dose.
The same site-wide sentence covers this product, and the rate objection applies with equal force: SURMOUNT-1 ran 72 weeks, so even its larger reduction averages well under a pound a week for any ordinary starting weight. There is a second problem specific to this row. The 15% figure comes from a SEMAGLUTIDE trial, and tirzepatide's own trial reported more than that — so a single blanket claim manages to overstate the rate for both products while understating the magnitude for one of them. A number applied to two different molecules is not a claim about either.2
Dispensing chain
Who actually fills your prescription
- Triad Rx — 26258 Pollard Road, Daphne, AL 36526, 251-380-7630, triadrx.us
- RedRock Pharmacy — 1240 E 100 S #220, St. George, UT 84790, 801-433-9500, redrockhomepharmacy.com
- Health Warehouse — 7107 Industrial Rd, Florence, KY 41042, 800-748-7001, healthwarehouse.com
- Precision Compounding Pharmacy — 2657 Merrick Road, Bellmore, NY 11710, 516-833-6262, mypcphealth.com
Read the full account
Re-checked 2026-08-25, and two things this review previously said are no longer true. SnagRx names four partner pharmacies, not one: Triad Rx in Daphne, Alabama, RedRock Pharmacy in St. George, Utah, Health Warehouse in Florence, Kentucky, and Precision Compounding Pharmacy in Bellmore, New York — each with a street address, a telephone number and a link to its own site, which most of the companies we track will not do at all. And the compounding category IS stated: the FAQ answer to "Where do my prescriptions come from?" says medications are "dispensed by U.S.-based 503A compounding pharmacies" working to USP 795 and USP 797, and adds that they "are not FDA-approved, but 503A compounding pharmacies are licensed by state pharmacy boards". That is the correct description, and it is better than the phrase the homepage still uses — compounded GLP-1s "produced in FDA-regulated facilities", which describes neither a 503A pharmacy nor a 503B outsourcing facility. The "US-Certified Pharmacy" badge still names no certifying body.
Read on the SnagRx site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result or testing laboratory is published. The nearest thing to a quality statement is the "US-Certified Pharmacy" badge, which names no certifying body, and the claim that the facilities are "highly regulated". Naming the pharmacy does leave a reader somebody to ask, which is more than most of the companies we track offer.
Read on the SnagRx site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Re-checked 2026-08-25: SnagRx does answer this, and this review previously said it did not. Its FAQ question "What States/Juristictions are eligible?" reads "SnagRx currently provides services to all US States except Louisiana. In Nebraska, services are limited to patients 19 years of age or older." A separate alert inside the signup repeats the Louisiana restriction. The shipping-state dropdown at the first intake question lists all fifty states plus the District of Columbia, Louisiana included, so the exclusion is stated in the FAQ and not enforced at the point you pick a state.
Read the full licensing claim
"Doctor-prescribed GLP-1 treatment", with a provider writing the prescription after intake and "on-going care & support with SnagRx Nursing Staff". No clinician is named and no licensing detail is published.
Named as outside that footprint
Read on the SnagRx site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with SnagRx
We went through SnagRx’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Press "Get started" on the home page. Two prices are already on it.
- One long screen asks your height, current weight, goal weight, shipping state, date of birth and sex.
- Two condition checklists follow on the same screen — 22 exclusions on the first, 11 on the second.
- Three yes/no questions: current medications, medication allergies, any recent GLP-1 use.
- A results screen: "You're a Great Fit for the SnagRx Program!", with a weight forecast and a wall of testimonials before the button.
- Pick what you want a companion medication to do — muscle, nausea, longevity, focus, energy, insulin resistance, sleep. No compound is named on the screen.
- Choose between "Affordability - Lowest Price" and "Potency - Stronger Medication".
- Say whether the medical team should know anything else.
- A "Your Medical Profile" screen prints your BMI and a chart running from today to your goal weight, then asks for first name, last name, email and phone with two consent boxes.
- The last screen approves you on a 15-minute clock, recommends semaglutide, offers four plan lengths and asks for shipping and billing addresses. This walk stopped there, before any card details.
- Two prices are public before a single question: semaglutide at $69 a month and tirzepatide at $119, each struck through from a higher figure.
- Neither headline is the month-to-month price. The plan screen at the end sets $99 a month with no commitment, $89 on three months, $79 on six, and the advertised $69 only on the twelve-month plan.
- The billing authorization charges every 28 days, not monthly, and shows on a card as OPNLP-SNAGRX. Thirteen charges land in a year, not twelve.
- The forecast is your own arithmetic handed back. Enter a 58 lb gap and it says "In 12 weeks, you could lose 58 lbs"; enter a 28 lb gap and it says 6 weeks. Both work out near 4.8 lb a week, which is roughly four times the "1-2lbs per week" the same company prints in its footer.
- "Congrats Testy, Your GLP-1 plan is approved!" appears the moment the contact form is submitted. The same screen says a board-certified physician reviews you after checkout, and the fine print says the assessment "does not create a doctor-patient relationship".
- The cheapest rung is a twelve-month plan on a page that also promises "No long contracts, cancel anytime", and the intake consent box says you are "enrolling in a subscription that automatically renews monthly unless I cancel".
SnagRx support
- Phone
- (469) 459-3723
- hello@snagrx.com
Assessment
What holds up, and what does not
- Its magnitude claim is close to the evidence: "up to 15%" sits between the −15.6% the registry records for STEP-1 and the −14.9% the published paper reports.
- It states plainly that compounded medications are "not FDA-approved or evaluated for safety, efficacy, or quality" — the exact disclosure two companies we've reviewed hold open FDA warning letters for omitting.
- It names four partner pharmacies, each with a street address, a phone number and a link to the pharmacy's own site.
Show 5 more
- Its FAQ states the compounding category outright — 503A, licensed by state pharmacy boards, working to USP 795 and USP 797 — which most of this category will not put in writing.
- It publishes its state coverage: every US state except Louisiana, with a minimum age of 19 in Nebraska.
- Its testimonial copy carries an unusually complete disclaimer: patients "exercised daily and ate a reduced-calorie diet", and "their fat loss is not typical".
- It names the molecule on both products rather than selling "a GLP-1" of unstated composition.
- No FDA warning letter under the brand, the operating company or the named pharmacy, checked 11 August 2026.
- "1-2lbs per week" is two to four times the average rate STEP-1 produced: 15.6% over 68 weeks is about 0.23% of starting weight a week, and no period is attached to the claim.
- One blanket figure — 15% — is applied to both semaglutide and tirzepatide, two molecules whose trials reported different results, so it cannot be an accurate claim about both.
- The 15% comes from a trial of the approved injectable, while SnagRx dispenses a compounded preparation that has never been through a registered trial. The disclosure exists, but not beside the number.
Show 8 more
- "Compounded GLP-1s are produced in FDA-regulated facilities" describes neither 503A pharmacies, which state boards license, nor 503B facilities, which register with FDA.
- The advertised headline price is the twelve-month rate. Walked on 25 August 2026, the plan screen charges more per month if you will not commit to a year.
- The checkout authorization bills every 28 days, not monthly — that is 13 charges in a year against a page selling itself by the month.
- The signup reads your own typing back as a forecast: enter a 58 lb gap and it promises 58 lb in 12 weeks, which is roughly four times the "1-2lbs per week" its own footer claims.
- "Your GLP-1 plan is approved!" appears on a 15-minute countdown before any clinician has seen it — the same screen says a physician reviews you after checkout, and the fine print says the assessment creates no doctor-patient relationship.
- The "US-Certified Pharmacy" badge names no certifying body.
- SnagRx and Embody are the same operating company by both footers, and nothing on either site tells a reader comparing them so.
- No certificate of analysis, lot number or testing result is published for either product.
Verdict
The bottom line
Price the month you are actually buying, not the one on the home page: the advertised figure is the twelve-month rate, and the authorization bills every 28 days. Then budget the time the same way — about 0.23% of your starting weight a week over 68 weeks, which is the trial's number, not the four-and-a-half pounds a week the signup forecasts back at you.
Opens snagrx.com. A link is not a recommendation to take anything.
Two claims in one sentence
SnagRx's footer promise:
"Lose up to 15% of your body weight (1-2lbs per week) with medically supervised safe & effective treatment from the comfort of your home."
Read as one claim it sounds coherent. Read as two, only one survives.
Full analysis — 7 more sectionsThe percentage is defensible · The weekly rate is not · One figure, two molecules · What it gets right · What a month actually costs · The forecast is your own typing · One company, two brands
The percentage is defensible
STEP-1 (NCT03548935) is the phase 3 trial of once-weekly semaglutide 2.4 mg in 1,961 adults. Registry-verified on 11 August 2026:
- Primary outcome — Change in Body Weight (%)
- Timeframe — Baseline (week 0) to week 68
- Result — −15.6% on semaglutide, −2.8% on placebo
The published paper reports −14.9% on a different estimand. Both are real; the difference is the analysis, not the trial. "Up to 15%" sits between them, which is more restraint than this category usually shows.
The weekly rate is not
15.6% spread across 68 weeks averages about 0.23% of starting body weight per week.
For "1-2 lbs per week" to equal 0.23% a week, a patient would have to start at roughly 435 to 870 lb. At any weight this drug is ordinarily prescribed at, one to two pounds a week is two to four times the average rate the trial produced.
Two things in fairness. Loss on these drugs is front-loaded, so the first weeks genuinely run faster than the 68-week average — the objection is that a peak rate is being presented as the rate, with no period attached. And this arithmetic deliberately avoids assuming a starting weight: the registry publishes the percentage and the timeframe, so the comparison is done proportionally rather than on a number nobody published.
One figure, two molecules
The same sentence sits above both products. But 15% comes from a semaglutide trial, and SnagRx also sells tirzepatide, whose own phase 3 program reported a larger reduction over 72 weeks. A single number applied to two different molecules overstates the rate for both and understates the magnitude for one. It is not a claim about either drug so much as a claim about the category.
What it gets right
"Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality."
That second sentence is the disclosure two companies we've reviewed hold open FDA warning letters for leaving out. SnagRx prints it unprompted.
The first sentence is looser than it sounds. A 503A pharmacy is licensed and inspected by its state board; a 503B outsourcing facility registers with FDA. Neither is "FDA-regulated" in the way a reader will hear it.
Its FAQ, however, gets it right where the home page does not. Re-checked 25 August 2026, the answer to "Where do my prescriptions come from?" says medications are "dispensed by U.S.-based 503A compounding pharmacies", names USP 795 and USP 797, and states that 503A pharmacies "are licensed by state pharmacy boards". Two sentences on one site, and only one of them describes the law.
It also names four pharmacies outright — Triad Rx in Daphne, Alabama, RedRock Pharmacy in St. George, Utah, Health Warehouse in Florence, Kentucky, and Precision Compounding Pharmacy in Bellmore, New York — each with a street address, a phone number and a link. Most of the companies we track never name one.
What a month actually costs
Walked on 25 August 2026, start to finish, with invented details and stopped before payment.
The home page sells semaglutide at $69 a month. That figure is real, and it is not a month-to-month price. At the end of the signup the plan screen puts four rungs side by side, all against the same struck-through anchor:
- No commitment — $99 a month, four weeks of medicine
- Three-month plan — $89 a month, twelve weeks
- Six-month plan — $79 a month, twenty-four weeks
- Twelve-month plan — $69 a month, forty-eight weeks
The advertised number is the bottom rung, and it costs a year of commitment. The same screen promises "No long contracts, cancel anytime".
Then read the authorization above the card fields. It charges "every 28 days on a recurring basis until you cancel" — so a "month" here is four weeks, thirteen of them fit in a year, and month-to-month runs $1,287 over twelve calendar months rather than the twelve payments the wording implies. Billing is handled by OpenLoop Health and lands on a statement as OPNLP-SNAGRX.
The forecast is your own typing
Halfway through the intake, after nothing more than height, weight and a goal, the screen says: "In 12 weeks, you could lose 58 lbs."
Fifty-eight pounds was the gap between the weight typed in and the goal typed in. Change the goal to a 28 lb gap and the sentence becomes "In 6 weeks, you could lose 28 lbs." Both come out near 4.8 lb a week — which is not the trial's rate, and is not even SnagRx's own claimed rate. Its footer says one to two pounds a week. Its signup promises roughly four times that, to whoever asks for it.
The screen after it reads "Congrats, Your GLP-1 plan is approved!" on a fifteen-minute countdown. Further down the same page: "After checkout, a board-certified physician will review your information and begin the approval process." And in the fine print: the assessment "does not create a doctor-patient relationship". Three statements, one screen, and the first one is the one in the large type.
One company, two brands
SnagRx's footer: "© 2026 SnagRx - Modern Metabolic Medicine, Inc."
Embody's footer: "Modern Metabolic Medicine, Inc. is the legal entity operating Embody (joinem.co)."
Same operator, same "$230 OFF every month" banner, same countdown clock, same $69 and $119 headline numbers. Nothing here claims the products are identical or the pharmacies shared — only that a reader treating these as two independent quotes is comparing one company with itself.
Questions
Frequently asked questions
Can you lose 1-2 lbs a week on compounded semaglutide?
Not as an average, on the evidence that exists. STEP-1 reported −15.6% of body weight over 68 weeks, which works out at roughly 0.23% of starting weight per week. For one to two pounds a week to match that, a patient would need to start at something north of 400 lb. Early weeks do run faster than the average because loss on these drugs is front-loaded, so a fast first month is not surprising — but presenting the peak rate as the rate, with no period attached, describes an outcome the trial did not produce.
Is "up to 15%" accurate?
Close, and unusually restrained for this category. The registry records STEP-1's primary outcome as −15.6% at week 68; the published paper reports −14.9% on a different estimand. "Up to 15%" sits between them. Two caveats: the trial tested Novo Nordisk's approved injectable rather than the compounded preparation SnagRx dispenses, and the same 15% is applied to its tirzepatide product, whose own trial reported a different result.
Is SnagRx the same company as Embody?
Yes, by both companies' own footers — SnagRx's names Modern Metabolic Medicine, Inc., and Embody's states that Modern Metabolic Medicine, Inc. is the legal entity operating Embody. They run the same promotional structure, the same discount banner and the same headline prices. That does not mean the products or pharmacies are the same, and nothing here claims they are; it means the two are not independent options.
Which pharmacy fills a SnagRx prescription?
Triad Rx, at 26258 Pollard Road, Daphne, AL 36526, 251-380-7630, published with a link to the pharmacy's own site. Naming it at all puts SnagRx ahead of most of the companies we've reviewed. What is missing is the compounding category — neither 503A nor 503B appears — and any certificate of analysis or testing result. Its "US-Certified Pharmacy" badge names no certifying body.
Glossary
Key terms
Show definitions
- Rate versus magnitude
- How fast weight comes off versus how much comes off in total. A trial reports magnitude over a stated period; dividing one by the other gives an average rate, which is lower than the early weeks and higher than the late ones. A weekly rate quoted without a period is the least checkable claim in this category.
- Estimand
- The precise question a trial's analysis answers — for instance, the effect of being assigned a treatment regardless of whether participants stayed on it, versus the effect of taking it as directed. STEP-1 reports −15.6% and −14.9% under two different estimands. Both are correct; they answer different questions.
- 503A pharmacy
- A compounding pharmacy licensed and inspected by its state board, preparing medicines for individual patients against a prescription. Its products are not FDA-approved and have not been evaluated by FDA for safety, effectiveness or quality.
Compare
Others selling what SnagRx sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off SnagRx's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.